RxDoctor Payments Data

Gary Bokinsky

Urology · Richmond, VANPI 1831152909

Payments from drug & device makers

$12,014in general payments, 2019–2025

Across 612 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$2K
  • Johnson & Johnson$1K
  • Astellas Pharma US Inc$899
  • Bayer$875
  • AbbVie$835
  • Pfizer$750
  • plus $6K from 45 others

What the payments were for

  • Food & beverage$12,014100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,014 in reported general payments places this provider in the 75th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$155,485
Medicare patients
628
Services billed
23,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron16$11,426
Tamsulosin Hcl373$4,889
Finasteride288$4,080
Dutasteride119$3,265
Testosterone19$2,854
Tolterodine Tartrate ErTolterodine Tartrate19$1,504
Potassium Citrate ErPotassium Citrate21$1,165
Alfuzosin Hcl ErAlfuzosin Hcl38$980
Oxybutynin Chloride14$569
Doxycycline Hyclate18$292
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$198
Cefdinir13$113
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim27$99
Oxybutynin Chloride ErOxybutynin Chloride11$65
Ciprofloxacin Hcl20$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$899$11,42616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 300 urology providers in Virginia.

Other urology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →